Ticker

New York, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering (the "Offering") of $12 million for its client China SXT Pharmaceuticals Inc.

TAIZHOU, China, Oct. 8, 2026 /PRNewswire/ -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the "Company"), today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 8,000,000 Class A ordinary shares of the company, no par value per share (the "Shares") (or pre-funded warrants in lieu thereof), at a purchase price of $1.50 per…

TAIZHOU, China, Aug. 05, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) (the “Company”), today announced that it will effect a share consolidation of its Class A ordinary shares, no par value per share, and Class B ordinary shares no par value per share, at a ratio of 1-for-80, effective on August 10, 2026 (the “Share Consolidation”). The Company's Class A ordinary shares are expected to…

New York, July 24, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering (the “Offering”) of approximately $9 million for its client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the "Company"), a China-based innovative pharmaceutical…

New York, July 24, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering (the "Offering") of approximately $9 million for its client China SXT Pharmaceuticals Inc.